Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...
BUFFALO, N.Y. (CN) - A woman says she suffered a "severe stroke" after taking Zelnorm, a Novartis drug prescribed for irritable bowel syndrome and constipation. The drug was pulled off the market when ...
ZURICH, March 30 (Reuters) - Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and ...
The FDA has agreed to permit limited use of Novartis’ Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drug’s voluntary withdrawal over cardiovascular ...
WASHINGTON (Reuters) - Novartis will further restrict access to its irritable bowel syndrome drug Zelnorm, reserving it for the sickest patients, the company and U.S. health regulators said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results